Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Alter Your Savvy Bed for A definitive Rest Insight - 2Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- 3Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- 4Your kid wants it now. What saying yes, no or not yet teaches kids about money and instant gratification.
- 5Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
- Vote in favor of Your #1 4\u00d74 SUVs
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Cyprus urges hotels to open up, pours funding into tourism
- Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
- Sound Maturing: Wellbeing Tips for Each Life Stage
- Accor signs agreement to transform El Gouna resort as Sofitel
- Vote In favor of Your Favored Menial helper Administration
- Spain and Catholic Church agree to compensate sex abuse victims
